Linkedin
Sign in
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Type here...
Search
Home
About
Editor’s Corner
Contribute
Contact Us
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
Solutions & Pricing
Partner
Instagram
Linkedin
Twitter
Subscribe
Subscribe
Friday, April 3, 2026
24.8
C
Bengaluru
Home
About
Editor’s Corner
Contribute
Contact Us
My account
Get into your account.
Login
Register
type here...
Search
Facebook
Linkedin
Twitter
Youtube
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Hot topics
IMS Health Market Reflection Report for July 2016
0
The Indian Pharmaceutical Market (IPM) was valued atRs. 10,025 crores in the month of July 2016 clocking a 14.7% growth over same period last year (SPLY). This was the first time ever the market crossed the 10,000 crore mark in a single month.
Astra Zeneca Tops Indian Pharma in New Introductions 2024
0
Analysis of Indian Pharmaceutical Market (IPM) – 2024 This data...
Managing Or Gardening? Great Managers Are Like Gardeners: Cultivating Growth in Teams
0
A great manager is not just a leader; they...
Astra Zeneca Tops Indian Pharma in New Introductions 2024
0
Analysis of Indian Pharmaceutical Market (IPM) – 2024 This data...
Semaglutide – More Than Just a Patent Battle
0
The Delhi High Court has restrained Dr. Reddy’s and...
Facebook
Linkedin
Twitter
Youtube
Healthcare Trends
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
0
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
0
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
0
Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
0
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Marketing
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
0
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
0
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
0
Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
0
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Policies/Sales
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
0
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
0
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
0
Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
0
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Strategy
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
0
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
0
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
0
Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
0
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Subscribe
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Hot topics
India’s Hospital Acquisitions Surge: RCML’s Pratiksha Deal Signals Expansion and Industry Trends
0
The healthcare sector in India has entered a dynamic...
Can Medicines Inject the Vitamins Amazon is Missing?
0
How Amazon’s Healthcare Bet May Change Indian Diagnostics and...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
0
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Fifth Aniversary Issue
0
Digital in Pharma Special Issue with Digital Marketing Case Study on Janssen's Me Without Migraine patient awareness campaign.
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
0
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
Facebook
Linkedin
Twitter
Youtube
Healthcare Trends
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
0
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
0
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
0
Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
0
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Marketing
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
0
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
0
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
0
Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
0
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Policies/Sales
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
0
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
0
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
0
Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
0
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Strategy
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
0
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
0
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
0
Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
0
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Subscribe
Healthcare News
AI in Healthcare
Biologics
Digital in Pharma
Exclusive Articles
Exclusive Report
Featured Article
Healthcare C-Suite Movements
IMS Monthly Market Reflection Report
Exclusive Articles
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
Anup Soans
-
April 3, 2026
Read More
Featured Article
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
Anup Soans
-
March 21, 2026
Read More
Healthcare News
How Smart Medical Reps Can Beat Bots
Anup Soans
-
March 11, 2026
Read More
Exclusive Report
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
Anup Soans
-
March 7, 2026
Read More
Exclusive Articles
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
Anup Soans
-
February 24, 2026
Read More
Exclusive Articles
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
Anup Soans
-
February 23, 2026
Read More
Load more